#renaldenervation holds tremendous promise as a treatment for #hypertension (#highbloodpressure) — but its adoption has been limited by one challenge: it doesn’t work for everyone. Some even have an increase in BP after #RDN. @geneticure has solved this.
https://t.co/9ZPcCge07b
@nikillinit The problem with most of PGx is that it's not very actionable. Doesn't fulfill the promise of directing towards a specific drug, for a specific disease, at point of care. We are changing that for hypertension at @geneticure
@superjz@geneticure Solving: Can we improve the outcomes for chronic non-communicable disease (COPD, CVD, Hypertension). Team from Mayo Clinic (who is an investor). Can I DM more details?
@lamckeown1@Medtronic A promising technology with the right genetic diagnostic to rule out non-responders. This technology is available from @geneticure and validated. As mentioned by the committee, efficacy (and ultimately reimbursement) will hinge on identifying the subgroup that will benefit
@LizzyLaw_ A promising technology with the right genetic diagnostic to rule out non-responders. This technology is available from @geneticure and validated. As mentioned by the committee, efficacy (and ultimately reimbursement) will hinge on identifying the subgroup that will benefit
@TCTMD_Caitlin@lamckeown1 A promising technology with the right genetic diagnostic to rule out non-responders. This technology is available from @geneticure and validated. As mentioned by the committee, efficacy (and ultimately reimbursement) will hinge on identifying the subgroup that will benefit
@bijans A promising technology with the right genetic diagnostic to rule out non-responders. This technology is available from @geneticure and validated. As mentioned by the committee, efficacy (and ultimately reimbursement) will hinge on identifying the subgroup that will benefit
. @geneticure has unlocked this mystery, making renal denervation a viable option for the roughly 700 million patients who would be genetic candidates. $MDT #MDT#renaldenervation
.@Geneticure Announces Technology to Drive an Estimated 250% Increase in Renal Denervation Adoption Using Genetic Screening to Rule Out Non-responders https://t.co/qCXGsQZnsW
#hypertension#renaldenervation